Table 2.

Assessment of the change in sensitivity and specificity of acute kidney injury biomarkers using contemporaneous measurements in patients admitted with a diagnosis other than sepsis or pneumonia compared to single biomarkers in isolation

Biomarker	Sensitivity (%)	Specificity (%)
Cys-C alone (in Group 2)	100	85.7
pNGAL alone (in Group 2)	100	57.1
C + P (in Group 2)	100	92.9
Cys-C alone (in Group 3)	60	85.7
pNGAL alone (in Group 3)	80	57.1
C + P (in Group 3)	20	92.9

C + P, Contemporaneous abnormal cystatin C (Cys-C) and plasma human neutrophil gelatinase-associated lipocalin (pNGAL)

For definition of groups, see Fig. 1b and section A biomarker panel improves specificity for acute kidney injury (AKI)